Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol DOI Creative Commons
Jiwon Yoon, Sanghyun Kim, Chan‐Young Kwon

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0319459 - e0319459

Published: April 1, 2025

The most common symptom reported by patients after recovery from coronavirus disease 2019 (COVID-19) is fatigue. However, robust clinical evidence supporting the effectiveness of treatments and interventions for fatigue in COVID-19 survivors lacking. This pilot trial aims to assess safety efficacy Kyungok-go, a herbal preparation targeting fatigue, recovering COVID-19. study will include 100 participants with persistent more than 12 weeks recovery. They be randomly allocated into two groups: Kyungok-go group (n = 50) placebo 50). or administered twice daily weeks, assessed at 4-week intervals. primary outcome change Fatigue Severity Scale score. Secondary outcomes cognitive function, physical quality life, depression, sleep quality, medication adherence, feasibility. first attempt investigate relieving related long COVID. results are expected contribute establishment knowledge base reveal potential medicine prescriptions managing sequelae Trial registration number: KCT0008789 .

Language: Английский

A single-cell RNA sequencing dataset of peripheral blood cells in long COVID patients on herbal therapy DOI Creative Commons
Karolina Hanna Prazanowska, Tae-Hun Kim, Jung Won Kang

et al.

Scientific Data, Journal Year: 2025, Volume and Issue: 12(1)

Published: Jan. 30, 2025

Language: Английский

Citations

0

Course of General Fatigue in Patients with Post-COVID-19 Conditions Who Were Prescribed Hochuekkito: A Single-Center Exploratory Pilot Study DOI Open Access
Kazuki Tokumasu, Nobuyoshi Matsuki, Yuki Otsuka

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1391 - 1391

Published: Feb. 19, 2025

Background: After the start of COVID-19 pandemic, general fatigue in patients with long COVID and post-COVID-19 conditions (PCC) became a medical issue. Although there is lack evidence-based treatments, Kampo medicine (traditional Japanese medicine) has gained attention Japan. At an outpatient clinic Japan specializing COVID, 24% all prescriptions were medicines, 72% hochuekkito. However, been no prospective, quantitative study on course PCC who prescribed The aim this was to clarify those patients. Methods: This included aged 18 years or older visited specialized at Okayama University Hospital consented participate after being We reviewed backgrounds patients, we evaluated patients' assessment scale person online. Results: Twenty enrolled from September December 2023. average age 42.9 (SD: 15.8 years) 12 (60%) female. hochuekkito administration, score decreased 35.9 5.9) initial visit 31.2 9.4) 8 weeks, indicating trend for improvement (difference: 4.7; 95% CI: 0.5-8.9). Conclusions: A observed hochuekkito, potential benefit such General can be classified as post-infectious syndrome considered condition qi deficiency medicine, which appropriately indicated.

Language: Английский

Citations

0

Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol DOI Creative Commons
Jiwon Yoon, Sanghyun Kim, Chan‐Young Kwon

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0319459 - e0319459

Published: April 1, 2025

The most common symptom reported by patients after recovery from coronavirus disease 2019 (COVID-19) is fatigue. However, robust clinical evidence supporting the effectiveness of treatments and interventions for fatigue in COVID-19 survivors lacking. This pilot trial aims to assess safety efficacy Kyungok-go, a herbal preparation targeting fatigue, recovering COVID-19. study will include 100 participants with persistent more than 12 weeks recovery. They be randomly allocated into two groups: Kyungok-go group (n = 50) placebo 50). or administered twice daily weeks, assessed at 4-week intervals. primary outcome change Fatigue Severity Scale score. Secondary outcomes cognitive function, physical quality life, depression, sleep quality, medication adherence, feasibility. first attempt investigate relieving related long COVID. results are expected contribute establishment knowledge base reveal potential medicine prescriptions managing sequelae Trial registration number: KCT0008789 .

Language: Английский

Citations

0